Lyophilized Injectable Drugs Market Size | Trends Report - 2032 

Lyophilized Injectable Drugs Market Size - By Drug type (Anti-infectives, Anticoagulants, Hormones), Indication (Autoimmune, Respiratory, Gastrointestinal, Oncology), Packaging Type (Vial), Distribution Channel, Delivery Type, Global Forecast, 2023-2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Forecast parameters

1.4&nbsp;&nbsp;&nbsp; COVID-19 impact analysis at global level

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data Sources

1.6.1&nbsp;&nbsp;&nbsp; Primary

1.6.2&nbsp;&nbsp;&nbsp; Secondary

1.6.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.2.2&nbsp;&nbsp;&nbsp;Unpaid sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Global lyophilized injectable drugs market 360&deg; synopsis, 2018 - 2032

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Regional trends

2.1.3&nbsp;&nbsp;&nbsp; Drug type trends

2.1.4&nbsp;&nbsp;&nbsp; Indication trends

2.1.5&nbsp;&nbsp;&nbsp; Type of delivery trends

2.1.6&nbsp;&nbsp;&nbsp; Packaging trends

2.1.7&nbsp;&nbsp;&nbsp; Distribution channel trends

Chapter 3&nbsp;&nbsp;&nbsp;Lyophilized Injectable Drugs Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Increasing prevalence of chronic diseases globally

3.2.1.2&nbsp;&nbsp;&nbsp;Growing research and development activities in the industry

3.2.1.3&nbsp;&nbsp;&nbsp;Increasing number of product approvals for lyophilized injectable drugs

3.2.1.4&nbsp;&nbsp;&nbsp;Technological advancements in lyophilized injectable drugs delivery system

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;Substantial number of product recalls of lyophilized drugs

3.2.2.2&nbsp;&nbsp;&nbsp;High costs associated with the manufacturing process

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By drug type

3.3.2&nbsp;&nbsp;&nbsp; By indication

3.3.3&nbsp;&nbsp;&nbsp; By type of delivery

3.3.4&nbsp;&nbsp;&nbsp; By packaging

3.3.5&nbsp;&nbsp;&nbsp; By distribution channel

3.4&nbsp;&nbsp;&nbsp; COVID- 19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.5.1&nbsp;&nbsp;&nbsp; U.S.

3.5.2&nbsp;&nbsp;&nbsp; Europe

3.6&nbsp;&nbsp;&nbsp; Technology landscape

3.7&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.8&nbsp;&nbsp;&nbsp; PESTEL analysis

3.9&nbsp;&nbsp;&nbsp; Patent landscape, 2022

3.9.1&nbsp;&nbsp;&nbsp; Top 10 patented lyophilized injectable drugs

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Company positioning matrix

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Strategic outlook matrix

4.6&nbsp;&nbsp;&nbsp; Strategy dashboard, 2022

Chapter 5&nbsp;&nbsp;&nbsp;Lyophilized Injectable Drugs Market Size and Forecast, By Drug type (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by drug type

5.2&nbsp;&nbsp;&nbsp; Anti-infectives

5.3&nbsp;&nbsp;&nbsp; Anti-neoplastics

5.4&nbsp;&nbsp;&nbsp; Anticoagulants

5.5&nbsp;&nbsp;&nbsp; Hormones

5.6&nbsp;&nbsp;&nbsp; Antiarrhythmics

5.7&nbsp;&nbsp;&nbsp; Other drug types

Chapter 6&nbsp;&nbsp;&nbsp;Lyophilized Injectable Drugs Market Size and Forecast, By Indication (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by indication

6.2&nbsp;&nbsp;&nbsp; Autoimmune diseases

6.3&nbsp;&nbsp;&nbsp; Respiratory diseases

6.4&nbsp;&nbsp;&nbsp; Gastrointestinal disorders

6.5&nbsp;&nbsp;&nbsp; Oncology

6.6&nbsp;&nbsp;&nbsp; Cardiovascular diseases

6.7&nbsp;&nbsp;&nbsp; Infectious diseases

6.8&nbsp;&nbsp;&nbsp; Metabolic disorders

6.9&nbsp;&nbsp;&nbsp; Other indications

Chapter 7&nbsp;&nbsp;&nbsp;Lyophilized Injectable Drugs Market Size and Forecast, By Type of Delivery (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by type of delivery

7.2&nbsp;&nbsp;&nbsp; Prefilled diluent syringes

7.3&nbsp;&nbsp;&nbsp; Multi-step devices

Chapter 8&nbsp;&nbsp;&nbsp;Lyophilized Injectable Drugs Market Size and Forecast, By Packaging (USD Million)

8.1&nbsp;&nbsp;&nbsp; Key trends, by packaging

8.2&nbsp;&nbsp;&nbsp; Vials

8.3&nbsp;&nbsp;&nbsp; Cartridges

8.4&nbsp;&nbsp;&nbsp; Prefilled devices

Chapter 9&nbsp;&nbsp;&nbsp;Lyophilized Injectable Drugs Market Size and Forecast, By Distribution Channel (USD Million)

9.1&nbsp;&nbsp;&nbsp; Key trends, by distribution channel

9.2&nbsp;&nbsp;&nbsp; Hospital pharmacy

9.3&nbsp;&nbsp;&nbsp; Retail pharmacy

9.4&nbsp;&nbsp;&nbsp; Online pharmacy

Chapter 10&nbsp;&nbsp;&nbsp;Lyophilized Injectable Drugs Market Size and Forecast, By Region (USD Million)

10.1&nbsp;&nbsp;&nbsp; Key trends, by region

10.2&nbsp;&nbsp;&nbsp; North America

10.2.1&nbsp;&nbsp;&nbsp; U.S.

10.2.2&nbsp;&nbsp;&nbsp; Canada

10.3&nbsp;&nbsp;&nbsp; Europe

10.3.1&nbsp;&nbsp;&nbsp; Germany

10.3.2&nbsp;&nbsp;&nbsp; UK

10.3.3&nbsp;&nbsp;&nbsp; France

10.3.4&nbsp;&nbsp;&nbsp; Spain

10.3.5&nbsp;&nbsp;&nbsp; Italy

10.3.6&nbsp;&nbsp;&nbsp; Belgium

10.3.7&nbsp;&nbsp;&nbsp; Netherlands

10.3.8&nbsp;&nbsp;&nbsp; Norway

10.3.9&nbsp;&nbsp;&nbsp; Switzerland

10.3.10&nbsp;&nbsp;&nbsp; Rest of Europe

10.4&nbsp;&nbsp;&nbsp; Asia Pacific

10.4.1&nbsp;&nbsp;&nbsp; Japan

10.4.2&nbsp;&nbsp;&nbsp; China

10.4.3&nbsp;&nbsp;&nbsp; India

10.4.4&nbsp;&nbsp;&nbsp; Australia

10.4.5&nbsp;&nbsp;&nbsp; South Korea

10.4.6&nbsp;&nbsp;&nbsp; Indonesia

10.4.7&nbsp;&nbsp;&nbsp; New Zealand

10.4.8&nbsp;&nbsp;&nbsp; Singapore

10.4.9&nbsp;&nbsp;&nbsp; Thailand

10.4.10&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

10.5&nbsp;&nbsp;&nbsp; Latin America

10.5.1&nbsp;&nbsp;&nbsp; Brazil

10.5.2&nbsp;&nbsp;&nbsp; Mexico

10.5.3&nbsp;&nbsp;&nbsp; Argentina

10.5.4&nbsp;&nbsp;&nbsp; Chile

10.5.5&nbsp;&nbsp;&nbsp; Colombia

10.5.6&nbsp;&nbsp;&nbsp; Rest of Latin America

10.6&nbsp;&nbsp;&nbsp; Middle East &amp; Africa

10.6.1&nbsp;&nbsp;&nbsp; South Africa

10.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

10.6.3&nbsp;&nbsp;&nbsp; UAE

10.6.4&nbsp;&nbsp;&nbsp; Egypt

10.6.5&nbsp;&nbsp;&nbsp; Iran

10.6.6&nbsp;&nbsp;&nbsp; Rest of Middle East &amp; Africa

Chapter 11&nbsp;&nbsp;&nbsp;Company Profiles

11.1&nbsp;&nbsp;&nbsp; Bristol Myers Squibb

11.2&nbsp;&nbsp;&nbsp; Gilead Sciences, Inc.

11.3&nbsp;&nbsp;&nbsp; Cipla Limited

11.4&nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche Ltd.

11.5&nbsp;&nbsp;&nbsp; Novo Nordisk A/S

11.6&nbsp;&nbsp;&nbsp; Sanofi

11.7&nbsp;&nbsp;&nbsp; Aurobindo Pharmaceuticals

11.8&nbsp;&nbsp;&nbsp; Fresenius SE &amp; Co. KGaA (Fresenius Kabi)

11.9&nbsp;&nbsp;&nbsp; Merck &amp; Co., Inc

11.10&nbsp;&nbsp;&nbsp; Zydus Group

11.11&nbsp;&nbsp;&nbsp; Vetter Pharma

11.12&nbsp;&nbsp;&nbsp; Takeda Pharmaceutical Company Limited

11.13&nbsp;&nbsp;&nbsp; Johnson &amp; Johnson Services, Inc. 
&nbsp;

Lyophilized Injectable Drugs Market

Request Discount

Industries

Information

Link

Global Headquarters